Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 3/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | TFPI | P10646 | 1/20 | 0.40 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.40 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29352758 | 0.83 | TLR2 (0.58) | TLR2F2BACE1OPRL1 | |
| SCHEMBL29473672 | 0.75 | OPRL1 (0.55) | F2PTH1RBACE1OPRL1TFPI | |
| SCHEMBL16407972 | 0.75 | TLR2 (0.51) | TLR2 | |
| SCHEMBL29972087 | 0.74 | KISS1R (0.56) | F2PTH1RBACE1OPRL1TFPI | |
| SCHEMBL29649210 | 0.74 | TFPI (0.56) | PTH1RBACE1TFPIVIPR1KISS1R | |
| SCHEMBL31026565 | 0.72 | OPRL1 (0.52) | F2OPRL1KISS1R | |
| SCHEMBL30974224 | 0.72 | OPRL1 (0.56) | F2PTH1RBACE1OPRL1 | |
| SCHEMBL30633108 | 0.72 | KISS1R (0.61) | TFPIVIPR1KISS1R | |
| SCHEMBL16407973 | 0.72 | TLR2 (0.46) | TLR2 | |
| SCHEMBL30974440 | 0.71 | OPRL1 (0.56) | F2OPRL1TFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170072037-A1 | Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making | THE UNIVERSITY OF TOLEDO (US) | 2017-03-16 | — | — | US | disclosed |
| US-20150024037-A1 | Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making | THE UNIVERSITY OF TOLEDO (US) | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170072037-A1 | Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making | CSGALNACT1, B3GAT3, LGALS3BP | TLR2 710/4885F2 4328/4885PTH1R 4882/4885 |
| US-20150024037-A1 | Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making | CSGALNACT1, GALNT1, DPAGT1 | TLR2 66/4885F2 4546/4885PTH1R 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.